BN Business News
Add your company to Business Communicator →

Business · 20/12/2018Updated: 10/17/2026 · 1 min read

FDA Extends Comment Period for Proposed Rule on Clinical Investigations

Summary

The Food and Drug Administration (FDA) is extending the comment period for a proposed rule regarding Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations, following a request for an extension from interested persons.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →